Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A
Open Access
- 24 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 18 (1), 1873056
- https://doi.org/10.1080/21645515.2021.1873056
Abstract
Dendritic cell (DC) vaccines are a safe and effective means of inducing tumor immune responses, however, a better understanding of DC biology is required in order to realize their full potential. Recent advances in DC biology have identified a crucial role for cDC1 in tumor immune responses, making this DC subset an attractive vaccine target. Human cDC1 exclusively express the C-type-lectin-like receptor, CLEC9A (DNGR-1) that plays an important role in cross-presentation, the process by which effective CD8+ T cell responses are generated. CLEC9A antibodies deliver antigen specifically to cDC1 for the induction of humoral, CD4+ and CD8+ T cell responses and are therefore promising candidates to develop as vaccines for infectious diseases and cancer. The development of human CLEC9A antibodies now facilitates their application as vaccines for cancer immunotherapy. Here we discuss the recent advances in CLEC9A targeting antibodies as vaccines for cancer and their translation to the clinic.Keywords
Funding Information
- Mater Foundation (N/A)
- National Health and Medical Research Council of Australia (1078987; 1082665)
- QLD Children’s Hospital Foundation (50323, 50312)
This publication has 60 references indexed in Scilit:
- The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected miceJCI Insight, 2012
- Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humansThe Journal of Experimental Medicine, 2011
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsThe Journal of Experimental Medicine, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsThe Journal of Experimental Medicine, 2011
- Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9AProceedings of the National Academy of Sciences of the United States of America, 2011
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensThe Journal of Experimental Medicine, 2010
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvantThe Journal of Experimental Medicine, 2009
- Identification of a dendritic cell receptor that couples sensing of necrosis to immunityNature, 2009
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectinJCI Insight, 2008
- CLEC9A Is a Novel Activation C-type Lectin-like Receptor Expressed on BDCA3+ Dendritic Cells and a Subset of MonocytesJournal of Biological Chemistry, 2008